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Introduction
The terms angiogenesis and vasculogenesis have been
used synonymously and both terms have been used to
characterize the general formation and development of
blood vessels. However, there is still no agreement on
the exact meaning of these two terms, vasculogenesis
and angiogenesis. Although they were well defined
(Cogle and Scott, 2004), their characteristic meanings
were not appropriately and uniformly utilized. Angio-
genesis has been used to describe immigration (or
migration) of angioblasts, development of endothelial
cells from pre-existing blood vessels (Benirschke and
Kaufmann 2000; Charnock-Jones et al., 2004), and
sprouting of endothelial cells (Pardanaud et al., 1989).
In all types of angiogenesis, either under physio-
logical or pathological conditions, endothelial cell
activation is the first process to take place, leading to
increased vascular permeability. The main goal of this
process is to supply new blood. Various factors affect
angiogenesis and vasculogenesis by autocrine or
paracrine and as wall as directly or indirectly stimulat-
ing proliferation and differentiation of endothelial pre-
cursor cells. (Millauer et al., 1993; Hanahan and Folk-
man, 1996; Ferrara, 2004).
So far, four different VEGF subtypes have been
described, VEGF-A to VEGF-D (Tammela et al.,
2005). When it was first described VEGF has been
thought to act as a vascular permeability factor (VPF)
(Senger et al., 1983). The first identified VEGF-A is a
disulphide-linked homodimeric glycoprotein that plays
an important role in the vasculogenesis, angiogenesis,
vascular permeability and vasodilatation (Cheung,
1997;Torry and Torry, 1997; Kingdom et al., 2000;
Vuorela et al., 1997)..VEGF is a heparin-binding
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growth factor known to bind directly to its surface
receptors. The receptors for the VEGF family are
VEGFR-1/Flt-1, VEGFR-2/KDR/Flk-1 and VEGFR-
3/Flt-4 have been identified in placental tissues (Coop-
er et al., 1995; Shore et al., 1997; Leach et al., 2002;
Vuckovic et al., 1996;). VEGFR-1 is the receptor for
PIGF, VEGF-A, and VEGF-B (Terman et al., 1992);
while VEGFR-2 for VEGF-A, VEGF-C and VEGF-D
(Joukov et al., 1996). VEGFR-3 is the receptor for
VEGF-C and VEGF-D which seems to play a role in
regulation of angiogenesis and lymphangiogenesis (Gu
et al., 2006). 
Multiple studies have shown that both receptors are
clearly involved in capillary formation and vascular
development during embryogenesis (Shalaby et al.,
1995; Ferrara, 2000; Hiratsuka et al., 2005).
VEGF and its two receptors, VEGFR-1 (Hanahan,
1997) and VEGFR-2 (Terman et al., 1992; Millauer et
al., 1993) are expressed in the endothelium of blood
vessels and contribute to vascular development and
regulation of vascular permeability (Terman et al.,
1992). The vasculogenic importance of two newly
detected receptors tryosine kinases Tie-1 and Tie-2,
angiopoietin receptors, has been studied (Sato et al.,
1995; Suri et al., 1996; Maisonpierre et al., 1997; 
Kayisli et al., 2006).
Recently, placental vasculogenesis and angiogene-
sis were reviewed and discussed in detail with differ-
ent aspects (Leach et al., 2002; Kaufmann et al., 2004;
Mayhew et al., 2004).
Another closely related protein, placenta growth
factor (PIGF), is abundantly expressed in the placenta
( Park et al., 1994) and has been extensively investi-
gated within the last decade (Dvorak et al., 1995;
Vuorela et al., 1997; Clark et al., 1998; Szukiewicz
et al., 2005).
In VEGF knockout mice (Ferrara, 2000) and in the
absence of VEGFR-2 no differentiation of precursor
cells into endothelial cells occurs during vasculogene-
sis (Shalaby et al., 1995). On the other hand, a muta-
tion in the locus of VEGFR-1 (Fong et al., 1995) does
not prevent generation of endothelial cells but results
in endothelial disorganization and abnormal vessel for-
mation during early embryo development. Knockout
experiments in mice have highlighted the importance
of VEGFR-2 for recruitment and early differentiation
of haemangiogenic cells into fetoplacental capillaries
(Shalaby et al., 1995) and of VEGFR-1 for subsequent
arrangement of early endothelial cells to form endothe-
lial tubes (Fong et al., 1995; Fong et al., 1999).
Moreover, the early appearance of macrophages
(Hofbauer cells) in the villous core which have been
affected the villous vascularisation (Demir and Erben-
gi, 1984) and described to regulate distinct trophoblast
functions (Cervar et al., 1999) and to express angio-
genic growth factors (VEGF) (Demir et al., 2004),
suggests a paracrine role for these cells during the first
stages of vasculogenesis (Demir et al., 1997; Demir et
al., 2006, 2007; Seval et al., 2007).
The aim of the present study was to investigate the
expression profile of VEGF and its receptors, VEGFR-
1 and-2 with angiopoietin receptors Tie-1 and Tie-2;
and to evaluate the molecular and morphological steps
during vasculogenesis and angiogenesis in the early
human placenta.
Materials and Methods
Samples of human placental tissues were obtained after legal ter-
mination of pregnancy by curettage for medical or psychosocial
reasons, which were unlikely to affect placental structure and func-
tion. None of the pregnant women received hormone treatment; all
were normal pregnancies. Tissues were supplied from the Depart-
ment of Obstetrics and Gynecology, Akdeniz University, and the
Clinic of Obstetrics and Gynecology, Government Hospital,
Antalya. Written consent was obtained from patients before the
procedure. Consent forms and protocols to use the tissue were
approved by the Ethical Committee of Medical Faculty of Akdeniz
University.
Tissue collection and storage. Samples of human placental tissues
from 29 women were studied. Tissue samples were obtained from
curettage material of uncomplicated normal pregnancies during
very early stages of pregnancy (22nd-48th day post conception, p.
c.). Samples were classified as described in our previous study
(Demir et al., 1989) using embryonic developmental details fol-
lowing the Carnegie classification (O'Rahilly and Tucker, 1973).
Immediately after vacuum curettage (no application of
prostaglandins) placental tissues were collected and divided into
three pieces in order to perform immunohistochemistry, western
blot and transmission electron microscopy. A total of four groups
[each defining different gestational ages; days 22-28 (4th week,
n=11), days 29-35 (5th week, n=8), days 36-42 (6th week, n=6),
days 43-49 (7th week, n=4)] of placental tissues were used for
semi-quantitative evaluation of immunohistochemical staining.
Additionally to these samples, three samples for 8th week pregnan-
cy were used only for western blotting analyses.
Electron microscopy. Samples of human placental tissues were
fixed by immersion in 2.5% glutaraldehyde in 0.1 M cacodylate
buffer (pH 7.4) at room temperature for 4 h and post-fixed in 1%
phosphate-buffered osmium tetroxide for 2 h (Demir, 1980). The
specimens were dehydrated in ascending concentrations of ethanol
and embedded in Araldite-epoxy resin. Semi-thin sections were
stained with toluidine blue. Ultra-thin sections were double-stained
with uranyl acetate and lead citrate (Demir et al., 2005) and exam-
ined with electron microscopes (Zeiss M10 and Leo 906).
Immunohistochemistry. Placental tissues were fixed in 4%
paraformaldehyde for 4-6 h and embedded in paraffin. Serial sec-
tions were collected on poly-L-lysine coated slides (Sigma, St.
Louis, MO, USA), dewaxed, dehydrated, and placed in citrate
buffer (pH 6; 1 l distilled water; 2.1 g citric acid, 15 ml NaOH).
Immunohistochemical detection procedures have been described
previously (Demir et al., 2002), and were slightly modified for our
antibodies. To unmask antigens, an antigen retrieval procedure was
performed by treating the samples in a microwave oven at 750 W
for 5 min twice. After cooling for 20 min at room temperature, the
sections were washed in phosphate buffered saline (PBS; pH 7.4).
To remove endogenous peroxidase activity, sections were kept in
3% hydrogen peroxide (Dako A/S, Glostrup, Denmark) for 30 min
436 R. Demir
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(3): 436 (435-445) 
10.2478/v10042-009-0100-5
and washed with PBS three times. The following primary antibod-
ies were used: monoclonal mouse anti-human VEGF (1:100; clone
C-1, Santa Cruz Biotechnology Inc, Santa Cruz Biotechnology,
CA, USA), polyclonal rabbit anti-VEGFR-1 /Flt-1 (1:200, cat 
# C17, Santa Cruz Biotechnology), monoclonal mouse anti-
VEGFR-2 (Flk-1/KDR) (1:200; clone A-3, Santa Cruz Biotechnol-
ogy) (Demir et al., 2004). Rabbit anti Tie-1 (1:200, polyclonal, SC-
342; Santa Cruz Biotechnology), rabbit anti Tie-2 (1:200, poly-
clonal, SC-324; Santa Cruz Biotechnology), monoclonal mouse
anti-human Tie-1 (25µg/ml, MAB619, R&D Systems), and mono-
clonal goat anti-human Tie-2 (25µg/ml, AF313, R&D Systems).
Monoclonal mouse anti-CD34 (ready to use (RTU), clone
QBEnd10, Dako A/S) and monoclonal mouse CD31 (ready to use
(RTU), clone 1A10, NeoMarkers, Fremont, CA, USA) were used
to identify endothelial cells. Monoclonal mouse anti-vimentin
(RTU, clone V9, Dako A/S) was used to identify cells of mes-
enchymal origin, anti-cytokeratin 7 (1:100, clone OV-TL12/30,
Dako A/S) to identify trophoblast, anti- CD68 (7.2 µg/ml, clone
PG-M1, Dako A/S) to identify Hofbauer cells. After 30 min incu-
bation with blocking solution, sections were incubated with the pri-
mary antibodies at 4°C overnight, followed by sequential 30 min
incubations with biotinylated secondary antibodies (Dako A/S) and
peroxidase labelled streptavidin. Immunohistochemistry was per-
formed using a horseradish-peroxidase labelled streptavidin biotin
(HRP-LSAB) kit (Dako A/S). The resulting signal was developed
with diaminobenzidine (DAB) (Dako A/S). All incubations were
performed in a moist chamber at room temperature, using PBS for
washes between the incubation steps. The sections were counter-
stained with Mayer's hematoxylin solution (Merck, Darmstadt,
Germany) and mounted with glycerol-gelatin (Sigma). Negative
control stainings were performed by replacing the primary anti-
bodies with the appropriate non-immune IgG or isotypes. To test
the antigenic specificity of the antibodies, Tie-1 and Tie-2 primary
antibodies were preincubated with their specific peptides (10µg/ml
dilution for Tie-1P (C-18), and 10µg/ml Tie-2P (C20), Santa Cruz
Biotechnology) for 1 h at 37oC. Then, the same protocol was
applied. (Kayisli et al., 2006).
Photomicrographs were taken with an Axioplan microscope
(Zeiss, Oberkochen, Germany). Tissue sections from different preg-
nancy days were evaluated for protein localization and intensity. All
samples for each individual antibody were exposed to the same pro-
tocol and were stained using the same duration of staining. 
The intensity of immunoreactivity was semi-quantitatively
evaluated as follows. Positively stained cells were grouped accord-
ing to the following categories: – (no staining) 1+ (weak but
detectable), 2+ (moderate or distinct), 3+ (intense). For each tissue,
an HSCORE value was calculated by summing the percentages of
cells grouped in one intensity category and multiplying this num-
ber with the weighted intensity of the staining, using the formula
[HSCORE= Pi (i+l)], where i represents the intensity scores and Pi
is the corresponding percentage of the cells. In each slide, five dif-
ferent areas were evaluated under a microscope using 400× origi-
nal magnification, the percentage of the cells for each intensity
within these areas was determined by two investigators who were
blinded to slides and gestational age, and the average score was
used (Demir et al., 2004).
Western blot technique. Western bloting procedures have been
described in our recent studies (Demir et al., 2004; Kayisli et al.,
2006) was applied. From placental tissues (3 samples for each ges-
tational week; 8th week was addition for WB), n=15) total protein
was extracted using a lysis buffer (50 mM HEPES, pH 7.4, 150
mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM
EGTA, 100 mM NaF, 10 mM sodium pyrophosphate and protease
inhibitors, 1mM Na3VO4, 10 mg/ml leupeptin, 10 mg/ml aprotinin,
and 4 mM PMSF). The protein concentration was determined 
by a detergent compatible protein assay (Bio-Rad Laboratories, 
Hercules, CA, USA). Samples (20 µg) were loaded and separated
by non-reducing SDS-polyacrylamide gel electrophoresis using
7.5%-12% Tris-HCl ready gels (Bio-Rad Laboratories) and elec-
troblotted onto Hybond ECL nitrocellulose membrane (Amersham
Pharmacia Biotech, Buckinghamshire, England). The membrane
was blocked with 5% non-fat dry milk in TBS-T buffer (0.05%
Tween-20 in TBS, pH 7.4) for 1 h to reduce non-specific binding.
Afterwards, the membrane was incubated for 1 h with monoclonal
antibodies against VEGF (Santa Cruz Biotechnology), Flk-1
(Santa Cruz Biotechnology) and Flt-1 (Santa Cruz Biotechnology),
and the polyclonal antibodies against Tie-1 (1/200; Santa Cruz
Biotechnology) and Tie-2 (1/200; Santa Cruz Biotechnology).
Following rinses with TBS-T for 15 min once and 10 min twice,
the membranes were further incubated for 1 h with peroxidase
labelled secondary antibodies (Vector Laboratories) diluted 
at 1:10000 and subsequently washed with TBS-T for 15 min once
and 10 min twice. The immunoblot was developed using a chemi-
luminescent kit (NEN Life Science, Boston, MA). Equal loading
was confirmed using Ponceau staining (Molecular Dynamics, Sun-
nyvale, CA).
Statistical analysis. Statistical analysis for immunohistochemical
and Western blot data were normally distributed (tested by Kol-
mogorov-Smirnov test) throughout the days of pregnancy tested.
Analysis of variance (ANOVA) and the Tukey tests and pair wise
multiple comparisons were carried out for statistical analysis. Sta-
tistical calculations were performed using the Statistical Package
for social sciences (SPSS, Chicago, IL, USA) and Sigmastat for
Windows, version 2.0 (Jandel Scientific Corporation, San Rafael,
CA, USA).
Results 
Immunohistochemical observations
Localization of VEGF and its receptors VEGFR-1
(Flt-1) and VEGFR-2 (Flk-1/KDR) proteins expres-
sion during the early pregnancy were examined by
immunocytochemistry on serial sections analysis. Dif-
ferent anti-VEGF and anti- VEGFR-1 and VEGFR-2
polyclonal antibodies, and the polyclonal antibodies
against Tie-1 and Tie-2 were used for each receptor.
VEGF expression in the early placental tree
VEGF immunoreactivity was mainly localized in
cytotrophoblastic cell layer of placental villi and to
angiogenic cell population forming primitive vascular
structures and in some stromal cells in the villi core
(Fig. 2a-d). The intensity of VEGF no immunostaining
was seen when the primary antibody was replaced by
preimmune rabbit IgG.
VEGFR-1 (Flt-1) expression in the early pla-
cental tree
During the placental development, VEGFR-1 
(Flt-1) immunoreactivity was detectable in the angio-
genic cell cords (ACC) dominantly all of the primitive
vascular tubes and angiogenic cells stained with CD31-
positive vascular structures (Fig. 1a and b). In the early
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days of pregnancy (between days 22-28), most of the
labeled ACC and primitive vascular tubes were not
main vascular patterns (capillary network) that had not
yet formed a lumen composed of elongated endothelial
cells (Fig. 1a-d). Their presence was assessed by
immunolabeling of serial tissue sections with several
specific endothelial markers, the anti-CD31 (Fig. 1a, b).
The intensity of the ACC and vascular patterns associat-
ed with immunostaining increased at the end of the villi
maturation periods; including mesenchymal villi (MV)
(Fig. 3a) that was differentiated into immature interme-
diate villi (IMIV) (Fig. 1a), and into to stem villi (SV)
segments of the placental villi tree development when
immunolabeling of VEGFR-1 was decreased observed
both on large vascular tubes and on vascular patterns
with a dilated lumen. The endothelium of a limited num-
ber of main vascular patterns localized in central areas of
core in SV segment was lightly labeled throughout the
placental development of early pregnancy.
During the early weeks (between 22-42 days) of
pregnancy, there was an increase in the intensity of
VEGFR-1-positive primitive vascular tube (connect-
ing tubes) strands in SV and IMIV and fully constitut-
ed single angiogenic cells and ACC in MV and IMIV
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Fig. 1. Representative pictures
showing first signs of vasculogenic
patterns in mesenchymal villi. (a, b)
Single cells (arrowheads) or cell
cords of vasculogenic patterns
(arrows) visualized by CD31
immunoreactivity are often seen in
close vicinity to the trophoblastic
cover. (c, d) Cytoplasmic processes
(asterisks in d) of the cells of vascu-
logenic patterns (VP) are seen in
semithin sections extending towards
the basement membrane (BM) of
cytotrophoblast cells (CT) [(d) is the
higher magnification of the area
selected by the rectangle-connected
arrow in (c)]. In the insert (b) the
ultrastructure of a single haeman-
giogenic stem cell can be seen.
These cells are characterized by
centrically positioned nucleus with
deep invaginations and a prominent
nucleolus, and abundant rouge
endoplasmic reticulum cisternae. 
(a) pregnancy day 37; (b) pregnancy
day 27; (c, d) pregnancy day 22 p.c.
(a, b, c) Scale bars= 50µm; (insert 
b and d) scale bar=4µm.
versus the staining (Fig. 3a). However, a similar
increase in the intensity of CD31 the main vascular
patterns structures were also observed. Consequently
the degree of the intensity of VEGFR-1-positive vas-
cular patterns to CD31 vascular structures was not sig-
nificantly different between the IMIV and MV;  with
the exception of the matured segment of stem villi. The
intensity of immunopositivity in SV was decreased
when compared to IMIV and MV segments of placen-
tal villi tree.  In the IMIV at the all days, a rich ACC
and primitive vascular tube network comprising all of
the vascular paterns strands and fully formed primitive
connecting tubes expressed VEGFR-1, along with the
endothelium of several main vascular structures local-
izing in central areas of IMIV. At the late days of preg-
nancy samples around day 42-48, there was a striking
decrease in the immunolabeling intensity of the
VEGFR-1-positive vascular patterns exhibited a dilat-
ed lumen on the period of pregnancy.
In addition to the findings in single angiogenic cell
and ACC (Fig. 1a, b), we observed a strong VEGFR-1
immunolabeling on stromal cells especially in Hof-
bauer cells and also in cytotrophoblastic layer as mod-
erate; and a lightly VEGFR-1 immunopositive in other
connective tissue cells (Fig. 2a, b). This labeling
decreased strongly due to segmental maturation of pla-
cental villi. The specific stromal cells population with
a irregular shape, a excentric nucleus, and the vacuo-
lated or un-vacuolated appearance and CD 68-positive
phenotype of cells of the Hofbauer cells (placental
macrophage) lineage were also immunoreactive for
VEGFR-1 in the IMIV for al of the specimens exam-
ined (Fig. 2c).
Hofbauer cells were numerous in the IMIV (Fig.
2c). Their distribution during the early days of preg-
nancy (between 22-48 days of pregnancy) were het-
erogeneous, and they were localized very near vascu-
lar patterns and close to ACC in small clusters in the
439VEGF and angiopoietin receptors in human placenta
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(3): 439 (435-445) 
10.2478/v10042-009-0100-5
Fig. 2. Representative pictures showing VEGF expression in dif-
ferent cell types during differentiation of the villous tree. (a) Vil-
lous cytotrophoblast cells (arrows) show a differential VEGF
expression related with the villous type [strong expression in mes-
enchymal (MV) and partly immature intermediate villi (IMV)].
Stromal cells (arrowheads) are also positive for VEGF in IMIV. 
(b) Later in villous development Hofbauer cells (arrows) become
strongly immunopositive for VEGF in IMIV; (c) their identifica-
tion is demonstrated by CD68 immunoreactivity (arrows). 
(d) HSCORE analysis revealed a significant increase in VEGF
immunoreactivity as pregnancy advanced (p<0.05). (a) pregnancy
day 26 pc; (b) pregnancy day 28 pc; (c) pregnancy day 30 pc. Scale
bar=50µm
IMIV; these cells, which secrete VEGF moderately
(Fig. 2c), expressed VEGFR-1 receptors strongly (Fig.
3a). During the development of these segments of pla-
cental villi, other stromal cells and cytotrophoblastic
layer were faintly immunolabeled, especially on the
villi segments of MV and IMIV (Fig. 3a, b), particu-
larly on days 22-42 of pregnancy.
VEGFR-2 (Flk-1/KDR) expression in the vil-
lous tree 
VEGFR-2 (Flk-1/KDR) was mainly localized to pla-
cental villi vascular structures. These are angiogenic
cells and Hofbauer cells and non vascular components
that were cytotrophoblastic layer and basic stromal
cells. No immunolabeling was seen when the primary
antibody was replaced by preimmune rabbit IgG.
VEGFR-2 vascular immunoreactivity was maximal
during the placental villi vascularization processes, as
shown by the higher intensity of stained vascular net-
work in the villi segments involved in the maturation
and complete vascularization, and the higher intensity
degree of VEGFR-2-positive to CD31 positive vascu-
lar patterns in the placental villi tree. 
During the vascular tube formation, VEGFR-2
expression was stronger than VEGFR-1 expression. At
the beginning of the ACC formation in the MV, the
majority of angiogenic cells strands and several primi-
tive vascular tube sections were labeled with the anti-
body against VEGFR-2; the totality of the vascular struc-
tures was immunostained in the IMIV segments (Fig.
3b). These angiogenic cells and primitive vascular tube
formation could be identified with anti-CD31 and CD34
antibodies (Fig. 1a, b). The intensity of VEGFR-2 stain-
ing persisted during the pregnancy advanced (Fig. 3d). 
In the IMIV and MV, vascular patterns immunore-
activity for VEGFR-2  was still observed; however,
while the intensity of VEGFR-2 positive vessels with
striking lumen was only slightly diminished, the inten-
sity staining of vascular patterns expressing the recep-
tor was considerably smaller owing to the overall
increase in placental vascular density indicating with
endothelial markers. The numbers of vascular patterns
stained for VEGFR-2 and for VEGFR-1 were there-
fore similar during the same placental villi segments.
The intensity of the immunolabeling was heteroge-
neous; it was lower in the SV segments, increased
strongly in the IMIV and MV. At the beginning of the
formation of MV, only a few angiogenic cells and
some ACC faintly expressed VEGFR-2. These struc-
tures were more intensely immuno-labeled on ACC in
IMIV segment of placental villi core (Fig. 3b). 
Light labeling of stromal cells and of cytotro-
phoblastic layer were also observed at some specific
segments of the placental villi. No significant labeling
was found in the cells during the entire in the IMIV
and MV (Fig. 3a, b); some intensely stained cells
appeared, however, in the SV ongoing in maturation.
Particularly striking was the immunolabeling of
numerous stromal cells of villous tree, some of which
had the appearance and immunophenotype for CD68,
Hofbauer cells. The cytotrophoblastic layer was
labeled with the anti-VEGFR-2 antibody, with an
accentuation of the staining in the basal portion, par-
ticularly at days 24-28 of pregnancy (Fig. 3b).
Tie-1 and Tie-2 expression in the villous tree
Tie-1 and Tie-2 immunoreactivities were evaluated for
villous types in placental villous tree including mes-
enchymal villi (MV) and immature intermediate villi
(IMIV). These proteins were analyzed by Western blot
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Fig. 3. Representative pictures
showing expression of VEGFR-1
and VEGFR-2 in different cell
types of the villous tree. 
(a) VEGFR-1 and (b) VEGFR-2 are
expressed by cytotrophoblast
(arrows) and by some stromal cells
(arrow heads) in mesenchymal villi
(MV) and immature intermediate
villi (IMV). There were no signifi-
cant changes in HSCORE evalua-
tions of (c) VEGFR-1, and 
(d) VEGFR-2 throughout pregnan-
cy weeks examined. (a) pregnancy
day 27; (b) pregnancy day 37, p.c.
Scale bar=50µm
technique. The intensity of immunoreactivities for Tie-
1 and Tie-2 was not change significantly in as preg-
nancy progressed. However, Tie-1 immunoreactivity
was stronger than Tie-2 in the stromal cells, but Tie-2
was strongest only in cytotrophoblastic layer in all
pregnancy days evaluated (Fig. 4).
Tie-1 expresion: Cytotrophoblastic layer and vari-
ous stromal cell varieties including fibroblast, angio-
genic cells cords and Hofbauer cells, indifferent mes-
enchymal cells showed the Tie-1 immunoreactivity in
MV and IMIV which was not alteration significantly
as pregnancy progressed. Cytotrophoblastic cell layer
and stromal cells in some villous segments was strong
immunostainning for Tie-1, but the Hofbauer cells
revealed a moderate immunoreactivity while indiffer-
ent mesenchymal cells displayed weak staining and no
significant alteration was observed as pregnancy pro-
gressed. Due to the segmental villous maturation Tie-1
expresion was decreased in vascular endothelium
when compared with the angiogenic cell cords in all
pregnancy weeks evaluated (Fig. 4a, c). The intensity
of Tie-1 immunoreactivity was gradually decreased
from MV towards SV in parallel to villous maturation
but not to the weeks of pregnancy (Fig. 4a, c).  
Tie-2 expresion: The main expresion sourse for
Tie-2 was definitly cytotrophoblastic cell layer in MV.
A strong immunoreactivity was observed in these cells
lined viili trofoblast and villi stroma including angio-
genic cell cords exhibited a moderate immunoreactiv-
ity for Tie-2 without significant alterations related to
the week of pregnancy. Due to the villi maturation and
development of placental villi large vascular paterns
were situated in central area of the aged villi.  The vas-
cular endothelium showed a decreasing from MV to
IMIV type for Tie-2. The cellular diversity with differ-
ent types in stroma displayed a gradual increasing
from absent to moderate for Tie-2 immunoreactivity as
pregnancy advanced (Fig. 4b, d).
Western blotting analysis of tie-1 and tie-2 were
showed, in general, a similar reaction in all of the ges-
tational days examined. Additional samples for west-
ern blotting between 50-56 days were analyzed. There
was an increase reaction for tie-1 between gestational
days of 50-56 examined; however this increasing was
not in significant difference for all of gestational days.
(Fig. 5)
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Fig. 4. Representative pictures
showing expression of Tie-1 and
Tie-2 in different cell types of the
villous tree. (a) Tie-1 and (b) Tie-2
are expressed by cytotrophoblast
(arrows) and by vasculogenic cell
patterns (VP) in mesenchymal villi
(MV) and immature intermediate
villi (IMV). A strong immunoreac-
tivity for Tie-2 was definitly seen in
cytotrophoblastic cell layer. (c) Tie-
1 and (d) Tie-2 HSCORE evalua-
tions revealed an increase as preg-
nancy progressed with a significant
increase in Tie-1 on the 6th week
(p<0.05).  (a) pregnancy day 30; (b)
pregnancy day 32, p.c. Scale
bar=50µm
Fig. 5. This Fig. is showing the western blotting analysis of tie-1
and -2 expression in early days of pregnancy. The immunoblot sig-
nals at around 120 kDa (for Tie-1) and 140 kDa  (for Tie-2) were
detected. They showed a little gradual increase in expresssion as
pregnancy progressed. No statistically significant differences can
be observed from the tie-1 and-2 bands when compared with 
ß-actin bands. 
Discussion
Our previous study on the expression of placental
VEGF and its receptors, VEGFR-1 (Flt-1) and
VEGFR-2 (Flk-1/KDR) has been carried out in very
early pregnancies with various gestational days
(Demir et al., 2004). In the present study we aimed to
determine, the expression profile of VEGF and its
receptors, VEGFR-1 and-2 with angiopoietin receptor
Tie-1 and Tie-2; and to evaluate the molecular and
morphological steps during vasculogenesis and angio-
genesis in the early human placenta.
The expression of the VEGF receptors that mediate
the functionality not only of the VEGF-A, but also of
other components of the VEGF family (PIGF, VEGF-
B, VEGF-C, VEGF-D). To perform a complete study
on the expression of the VEGF and its receptors, with
angiopoietin receptor Tie-1 and Tie-2; we used differ-
ent investigation methods, such as immunohistochem-
istry, electron microscope and Western blot. 
The findings obtained in the very early placental
samples were compared with those observed in tissue
samples of late early days of pregnancies.
The immunohistochemistry results showed that
VEGF and its receptors VEGFR-1 and VEGFR-2 were
not localized in all of the placental components was
detected only in the cytotrophoblast cells lined the villi
surface, in the ACC cords, in Hofbauer cells and pre-
endothelial cells forming primitive vascular patterns.
These findings are partially in agreement with previ-
ous investigations (Cooper et al., 1995; Clark et al.,
1998; Cheung, 1997; Shore et al., 1997; Dunk and
Ahmed, 2001).
The location of VEGFR-1 and VEGFR-2 in the pla-
centa early days (between 22-35 p.c.) of pregnancy,
was the same with respect to the late days (between
32-48 p.c.) of pregnancy. In the maturation period
advanced in some villi, particularly in stem villi type,
some segments of trophoblast and/or some vessels
and/or clusters of stromal cells did not express the
VEGF and its receptors, as demonstrated by the
immunohistochemical observation in each MV and
IMIV. The intensity of immunoreactivity of some pos-
itive components was significantly lower in all the
pregnancy days, particularly in the late days of the
examined. As regards the VEGFR-2, its expression
was detected, not only in the primitive vascular struc-
tures, but also in the cytotrophoblastic layer and in the
stromal cells. However, the ACC in MV and IMIV of
all the days of pregnancy showed a significant higher
intensity of immunoreactivity with respect to the
matured stem villi segments.
The Western blotting technique shoved that, the
protein levels of VEGF and its receptors VEGFR-1,
VEGFR-2 in the all examined gestational age, no dif-
ference showed a statistically significant when com-
pared with the each other. 
As regards the proteins expression levels, the data
showed a decrease of all the Tie-1 and Tie-2 receptors
from the 4 weeks placentas to the 7 weeks even if not
always significantly. The findings of this study demon-
strated that the expression of the VEGF and its recep-
tors and angiopoietin receptors Tie-1 and Tie-2 seem to
be related to the different degree of pregnancy days.
According to our results, the angiopoietin receptors
Tie-1 and -2 showed a higher expression levels in
respect to other study factors. The receptors protein
levels increased from the early days to the advanced
days of gestation, but this alteration was not signifi-
cant. The intensity of the immunolabeling for these
proteins were not significant compared to each other of
gestation days were examined.
Our knowledge regarding the placental expression
of the VEGF and its receptors in the pathological dis-
orders is discordant. In fact that studies carried out on
placentas from pathological pregnancies complicated
by different degrees of clinical severity, showed that
the hypoxic environment up-regulates VEGF and its
receptors (Helske et al., 2001; Kumazaki et al., 2002;
Tsatsaris et al., 2003). On the contrary, some authors
demonstrated that VEGF and VEGFR-1 are down-reg-
ulated in placentas of pregnancies with severe patho-
logical conditions (Zhou et al., 2002), and studies
about the influence of hypoxia on placental tissue have
demonstrated that VEGF-A is up-regulated, while
VEGFR-1 is down-regulated (Ahmed et al., 2000).
Moreover, some investigations have showed that an
increase in VEGF-A, together with other factors, may
lead to the structural alterations involved in the func-
tional processes of the placental tissue (Brockelsby et
al., 2000; El-Salahy et al., 2001; Redman and Sargent,
2001). From these discordant data it could be hypoth-
esized that an overproduction of VEGF-A in a definite
period of gestation might lead to the alteration of the
placental tissue, and that only the placental undamaged
components might continue to overproduce VEGF-A
(Sgambati et al., 2004). 
In the placenta of pregnancies from very early days,
a compensatory mechanism against the hypoxic envi-
ronment should be occurs, with an increasing production
of all the receptors levels and of the placental compo-
nents that produce VEGF and its receptors. It was sug-
gested that the mRNA levels of the receptors are not par-
alleled by the protein expression, as revealed by
immunohistochemistry and by western blotting (Sgam-
bati et al. 2004). According to alteration of protein syn-
thesis for VEGF and its receptors, it is possible to be the
slight functional changes of the placental components. In
the cases of full term human placental barrier, a more
severe structural complication characterized by evident
ultrastructural alterations (Demir 1979, 1980), only
some placental components might be able to make 
a function like-nefro-pneumoid units for transportation
442 R. Demir
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(3): 442 (435-445) 
10.2478/v10042-009-0100-5
and secretion of some substances (Demir et al.1995). 
Due to the different pathological condition, the
immunohistochemistry showed that in the some com-
ponents of placenta were positive for VEGF and its
receptors (Tsokos et al., 2002; Zhou et al., 2002). It
was possible to hypotheses that there is probably dam-
age in the placental components involved in as triggers
by a hypoxic environment. Due to this structural dam-
age during placental development, as a similarity, it is
possible to elicit an over expression for VEGF and its
VEGFR-1 and VEGFR-2 by the placental elements,
so, it is possible that partially damaged, in the attempt
of a compensatory mechanism for placental health vas-
cularization. 
The first vasculogenesis in the chorionic villi tree
starts at days 21 post conception, during the stage of a
4 somite embryo. At this stage, in the villi core, hae-
mangiogenic stem cells derived from mesenchymal
cells differentiate prior to the formation of first vessels
rather than originating from blood monocytes (Demir
et al., 1989). In the attempt to clarify the disagree-
ments of the data on the placental VEGF and its recep-
tors affected angiogenesis and vasculogenesis.
We have shown that a variety of factors are associ-
ated with placental angiogenesis and vasculogenesis.
Under the light of our and other data this study focus-
es on describing an integrated view on VEGF and its
some receptors in early placental of pregnancy. 
The results of this study are partially in agreement
with previous studies on the expression of VEGF  and
its receptors in placenta of pregnant with normal preg-
nancy (Ahmed et al. 2000) and not accordance preg-
nant with pathological disorders (Helske et al., 2001;
Kumazaki et al., 2002; Tsatsaris et al., 2003 Sgambati
et al., 2004). As reported in our recently study on the
VEGF-A and its receptors (Demir et al., 2004) and anti
angiopoietin receptors Tie-1 and Tie-2 expression
(Kayiºli et al., 2006), the disagreements might be due
to an assemblage in the same study group cases of
pathological disorders with different degree of clinical
severity.
In conclusion, we demonstrated that in the 
placental tissue from very early pregnancies there is 
a dysregulation of the expression of the VEGF and its
family receptors 1 and 2 and angiopoietin receptors
Tie-1 and Tie-2 related to the different degree of villi
type in developmental severity stages. However, the
VEGF and its receptors with angiopoietin receptors
Tie-1 and Tie-2 seem to play an important role in the
placental vascularization during the pregnancy. We
believe that, it should be necessary to perform studies
also on the expression of other factors of the VEGF
family, as well as of the receptor VEGFR-1s (soluble)
that has been shown to be up regulated in pathologi-
cal conditions (Helske et al., 2001; Kumazaki et al.,
2002; Tsatsaris et al., 2003).  
The functional investigations may be establish 
a communication between placental villi angiogenesis
and vasculogenesis during early days of pregnancy,
and probably to shove a relationship with the role
played by all the members of VEGF family in the ges-
tational complications of different clinical severity.
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